March 10, 2013
/PRNewswire/ -- Abbott (NYSE: ABT) today announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company's first-in-class catheter-based MitraClip
System for the treatment of mitral regurgitation (MR). Findings were presented today at the 62nd Annual Scientific Session of the American College of Cardiology in
Abbott's MitraClip system, an investigational device in
the United States
, received CE Mark in 2008 and is commercially available in approximately 30 countries, with more than 8,000 patients treated to date. The device is delivered to the heart through the femoral vein, a blood vessel in the leg, and is designed to reduce MR by clipping together the leaflets of the mitral valve to allow the heart to more efficiently pump blood.
The EVEREST II High Surgical Risk cohort included data from patients enrolled in the multi-center EVEREST II High Risk and REALISM continued access studies. Findings from 351 symptomatic U.S. patients deemed too high risk for open mitral valve surgery demonstrated:
- A 30-day mortality rate significantly lower than expected for surgery (4.8 percent for patients treated with the MitraClip system versus 18.2 percent predicted surgical mortality, p<0.0001);
- A low rate of adverse events, despite the high surgical risk profile of the patients
- An implant success rate of 96 percent;
- Acute reduction in MR to 2+ or less achieved in 86 percent of patients treated with the MitraClip device;
- Clinically significant improvement in left ventricular size, significant improvements in NYHA Functional Class and SF-36 Quality of Life scores, and significantly reduced rates of hospitalization for heart failure (48 percent reduction from one year post-discharge compared to the year prior to treatment, p<0.0001).
"Patients with mitral regurgitation who are not candidates for mitral valve surgery due to risk of mortality have an unmet need for a treatment option that will reduce symptoms and improve the quality of their lives," said
D. Scott Lim
, M.D., associate professor of Cardiovascular Medicine at the
University of Virginia
Health System in
"The findings of the EVEREST II High Surgical Risk cohort suggest that treatment with the MitraClip device represents a new option that could allow these high-risk patients to return to activities they enjoy, and results in a reduction in hospitalizations for heart failure."
"These results add to the large and growing body of data that show that the first-in-class percutaneous MitraClip therapy can have positive results for high surgical risk patients suffering from the debilitating symptoms of significant mitral regurgitation," said
Charles A. Simonton
, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "We look forward to the
FDA Advisory Committee meeting to discuss the MitraClip system as a treatment option for this patient group in
the United States
About Mitral Regurgitation
Mitral regurgitation (MR) is the most common type of heart valve insufficiency, affecting approximately one in 10 people aged 75 years and older. The condition occurs when the leaflets of the mitral valve do not close completely, causing blood to flow backward and leak into the left atrium of the heart during the cardiac cycle. To maintain an adequate forward flow of blood throughout the body, the heart compensates by increasing the size of the left ventricle, its main pumping chamber. This requires the heart to work harder, and may ultimately lead to irregular heartbeats, stroke, heart attack or death. MR may also lead to heart failure, a potentially deadly condition that occurs when the heart is unable to pump sufficiently to distribute blood flow to meet the needs of the body.
About the MitraClip System
Abbott's MitraClip device is designed to reduce MR and provide clinical and quality-of-life benefits for patients suffering from the debilitating symptoms of significant MR by clipping together the leaflets of the mitral valve. The device is delivered to the heart through the femoral vein, a blood vessel in the leg. The heart beats normally during the procedure, and a heart-lung bypass machine is not required. By reducing MR, the therapy may allow the heart to recover from overwork and improve function, potentially halting the progression of heart failure and enabling patients to live a higher-quality life.
The device received CE Mark in 2008 and is commercially available in approximately 30 countries, with more than 8,000 patients treated to date. The European Society of Cardiology (ESC) 2012 heart failure guidelines and the ESC/European Association for Cardio-Thoracic Surgery 2012 guidelines for the management of valvular heart disease specify the MitraClip system as a treatment option for high surgical risk patients with MR.